Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy- The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group Randomized Phase III study AML

B. Lowenberg; S. Suciu; E. Archimbaud; H.L. Haak; P. Stryckmans; R. de Cataldo; A.W. Dekker; Z. Berneman; A. Thyss; J. van der Lelie; P. Sonneveld; G. Visani; G. Fillet; M. Hayat; A. Hagemeijer; G. Solbu; R. Zittoun

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy- The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group Randomized Phase III study AML

Translated title of the contribution: Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy- The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group Randomized Phase III study AML

B. Lowenberg, S. Suciu, E. Archimbaud, H.L. Haak, P. Stryckmans, R. de Cataldo, A.W. Dekker, Z. Berneman, A. Thyss, J. van der Lelie, P. Sonneveld, G. Visani, G. Fillet, M. Hayat, A. Hagemeijer, G. Solbu, R. Zittoun

Hematology/Van Creveldclinic

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy- The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group Randomized Phase III study AML
Original language	Undefined/Unknown
Pages (from-to)	872-881
Number of pages	10
Journal	Journal of Clinical Oncology
Volume	16
Publication status	Published - 1998

Cite this

Lowenberg, B., Suciu, S., Archimbaud, E., Haak, H. L., Stryckmans, P., de Cataldo, R., Dekker, A. W., Berneman, Z., Thyss, A., van der Lelie, J., Sonneveld, P., Visani, G., Fillet, G., Hayat, M., Hagemeijer, A., Solbu, G., & Zittoun, R. (1998). Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy- The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group Randomized Phase III study AML. Journal of Clinical Oncology, 16, 872-881.

Lowenberg, B. ; Suciu, S. ; Archimbaud, E. et al. / Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy- The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group Randomized Phase III study AML. In: Journal of Clinical Oncology. 1998 ; Vol. 16. pp. 872-881.

@article{b2fee9942e914b66a2965bc3e7fd68ce,

title = "Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy- The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group Randomized Phase III study AML",

author = "B. Lowenberg and S. Suciu and E. Archimbaud and H.L. Haak and P. Stryckmans and {de Cataldo}, R. and A.W. Dekker and Z. Berneman and A. Thyss and {van der Lelie}, J. and P. Sonneveld and G. Visani and G. Fillet and M. Hayat and A. Hagemeijer and G. Solbu and R. Zittoun",

year = "1998",

language = "Undefined/Unknown",

volume = "16",

pages = "872--881",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins",

}

Lowenberg, B, Suciu, S, Archimbaud, E, Haak, HL, Stryckmans, P, de Cataldo, R, Dekker, AW, Berneman, Z, Thyss, A, van der Lelie, J, Sonneveld, P, Visani, G, Fillet, G, Hayat, M, Hagemeijer, A, Solbu, G & Zittoun, R 1998, 'Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy- The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group Randomized Phase III study AML', Journal of Clinical Oncology, vol. 16, pp. 872-881.

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy- The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group Randomized Phase III study AML. / Lowenberg, B.; Suciu, S.; Archimbaud, E. et al.
In: Journal of Clinical Oncology, Vol. 16, 1998, p. 872-881.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy- The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group Randomized Phase III study AML

AU - Lowenberg, B.

AU - Suciu, S.

AU - Archimbaud, E.

AU - Haak, H.L.

AU - Stryckmans, P.

AU - de Cataldo, R.

AU - Dekker, A.W.

AU - Berneman, Z.

AU - Thyss, A.

AU - van der Lelie, J.

AU - Sonneveld, P.

AU - Visani, G.

AU - Fillet, G.

AU - Hayat, M.

AU - Hagemeijer, A.

AU - Solbu, G.

AU - Zittoun, R.

PY - 1998

Y1 - 1998

M3 - Article

SN - 0732-183X

VL - 16

SP - 872

EP - 881

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Lowenberg B, Suciu S, Archimbaud E, Haak HL, Stryckmans P, de Cataldo R et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy- The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group Randomized Phase III study AML. Journal of Clinical Oncology. 1998;16:872-881.